Cabaletta to present CABA-201 preclinical data and DSG3-CAART update at ASGCT

Cabaletta Bio, Inc.

Oral presentation on CD19 CAR T for SLE by CSO Samik Basu at ASGCT on May 16.
New preclinical data for CABA-201 (CD19 CAR T) shows comparable activity to FMC63 construct.
Updated DSG3-CAART clinical data shows enhanced persistence with IVIG/cyclophosphamide preconditioning.
Poster presentations on May 18 and 19; abstracts published on ASGCT website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.